Autoimmune Genomics DxTerity focuses on real-world genomics for autoimmune diseases, including lupus, with the IFN-1 test as a flagship offering. This positions the company to target healthcare providers, clinics and biopharma partners seeking genomic diagnostics and biomarker panels to guide autoimmune disease management and trial enrollment.

Strategic Partnerships Past collaborations with Lupus Research Alliance, Amazon, and Xencor demonstrate the ability to co-develop, distribute, and co-market diagnostics across multiple channels. This suggests sales opportunities through strategic partnerships, licensing deals, white-label products, and access programs with distributors, patient networks, or pharmaceutical partners.

At-Home & Workplace Experience launching at-home and workplace testing programs shows operational versatility and consumer reach. This enables sales plays around corporate wellness programs, employer-sponsored screening, and consumer-direct autoimmune risk testing via retail or direct-to-consumer channels.

Growth & Scale Limited revenue and a very small team indicate a need for scalable partnerships with established lab networks or contract manufacturers. There are opportunities for co-development, white-labeling, or outsourcing to accelerate go-to-market with larger distributors, CROs, or integrated healthcare providers.

Tech & Data Illumina sequencing capability and a data-driven tech stack position DxTerity as a potential partner for precision medicine trials and genomic data services. Target pharma, research organizations, and health systems that require sequencing workflows, data analytics, and secure distribution for genomic diagnostics and real-world evidence collection.